These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35990692)

  • 1. Case report: Safety and efficacy of adalimumab in treating difficult-to-treat rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year follow-up.
    Chen JW; Deng GS; Zhang WS; Zhang MY; Guan T; Xu Q
    Front Immunol; 2022; 13():942642. PubMed ID: 35990692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis.
    Chen JW; Zhang WS; Lin CS; Xu Q
    Front Immunol; 2022; 13():1074329. PubMed ID: 36591263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV/AIDS and rheumatoid arthritis.
    Cunha BM; Mota LM; Pileggi GS; Safe IP; Lacerda MV
    Autoimmun Rev; 2015 May; 14(5):396-400. PubMed ID: 25578483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of a tumor necrosis factor inhibitor-adalimumab-in the management of arthritis in an adolescent with HIV: A case report.
    Bakry R; Bokhary N; Sendi E; Alshehri M; Sindi L; Alkwai H
    Int J Rheum Dis; 2024 Jan; 27(1):e14827. PubMed ID: 37431718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review.
    Liang SJ; Zheng QY; Yang YL; Yang Y; Liu CY
    Rheumatol Int; 2017 Jul; 37(7):1207-1212. PubMed ID: 28255643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful use of antitumor necrosis factor-alpha biological therapy in managing human immunodeficiency virus-associated arthritis: three case studies from Saudi Arabia.
    Almoallim H; Jali I; Wali G
    Joint Bone Spine; 2013 Jul; 80(4):426-8. PubMed ID: 23453475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Percentage of Signal Regulatory Protein α/β
    Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
    Front Immunol; 2018; 9():2865. PubMed ID: 30568660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A reexamination of the relationship between active rheumatoid arthritis and the acquired immunodeficiency syndrome.
    Ornstein MH; Kerr LD; Spiera H
    Arthritis Rheum; 1995 Nov; 38(11):1701-6. PubMed ID: 7488293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.
    Downey C
    Int J Rheum Dis; 2016 Jun; 19(6):536-50. PubMed ID: 26200188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.
    Inanc N; Direskeneli H
    Rheumatol Int; 2006 Nov; 27(1):67-71. PubMed ID: 16896990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 19. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
    Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC
    Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.